Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Morrow

Showing results (611-620 of 942) with videos related to

Pageof 95
Sort By:
Fundamental & Clinical Pharmacology|January 7, 2012
Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniquesFaiez Zannad, Guy De Backer, Ian Graham, et al.
Circulation|April 17, 2002
Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptideMarc S Sabatine, David A Morrow, James A de Lemos, et al.
Stroke|February 12, 2013
Efficacy and safety of vorapaxar in patients with prior ischemic strokeDavid A Morrow, Mark J Alberts, Jay P Mohr, et al.
Journal of the American Heart Association|August 30, 2019
Derivation and Validation of a Novel Cardiac Intensive Care Unit Admission Risk Score for MortalityJacob C Jentzer, Nandan S Anavekar, Courtney Bennett, et al.
Circulation|September 5, 2015
Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50Erin A Bohula, Philip E Aylward, Marc P Bonaca, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 6, 2016
Perfusion reduction in the absence of structural differences in cognitively impaired versus unimpaired RRMS patientsSeyed-Parsa Hojjat, Charles Grady Cantrell, Timothy J Carroll, et al.
Neuroradiology|June 18, 2017
Normal appearing white matter permeability: a marker of inflammation and information processing speed deficit among relapsing remitting multiple sclerosis patientsEldar Eftekhari, Seyed-Parsa Hojjat, Rita Vitorino, et al.
Circulation|July 10, 2002
Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial InfarctionGraham C Wong, David A Morrow, Sabina Murphy, et al.
Pediatrics|February 27, 2020
Tracheostomy in Very Low Birth Weight Infants: A Prospective Multicenter StudySam M Han, Karen F Watters, Charles R Hong, et al.
American Heart Journal|May 17, 2005
Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trialJessica L Mega, David A Morrow, Marc S Sabatine, et al.
Pageof 95

Showing results (611-620 of 942) with videos related to

Sort By:
Pageof 95
Fundamental & Clinical Pharmacology|January 7, 2012
Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniquesFaiez Zannad, Guy De Backer, Ian Graham, et al.
Circulation|April 17, 2002
Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptideMarc S Sabatine, David A Morrow, James A de Lemos, et al.
Stroke|February 12, 2013
Efficacy and safety of vorapaxar in patients with prior ischemic strokeDavid A Morrow, Mark J Alberts, Jay P Mohr, et al.
Journal of the American Heart Association|August 30, 2019
Derivation and Validation of a Novel Cardiac Intensive Care Unit Admission Risk Score for MortalityJacob C Jentzer, Nandan S Anavekar, Courtney Bennett, et al.
Circulation|September 5, 2015
Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50Erin A Bohula, Philip E Aylward, Marc P Bonaca, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 6, 2016
Perfusion reduction in the absence of structural differences in cognitively impaired versus unimpaired RRMS patientsSeyed-Parsa Hojjat, Charles Grady Cantrell, Timothy J Carroll, et al.
Neuroradiology|June 18, 2017
Normal appearing white matter permeability: a marker of inflammation and information processing speed deficit among relapsing remitting multiple sclerosis patientsEldar Eftekhari, Seyed-Parsa Hojjat, Rita Vitorino, et al.
Circulation|July 10, 2002
Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial InfarctionGraham C Wong, David A Morrow, Sabina Murphy, et al.
Pediatrics|February 27, 2020
Tracheostomy in Very Low Birth Weight Infants: A Prospective Multicenter StudySam M Han, Karen F Watters, Charles R Hong, et al.
American Heart Journal|May 17, 2005
Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trialJessica L Mega, David A Morrow, Marc S Sabatine, et al.
Pageof 95